(detection,2.8701690505786455)
(mammography,2.8701690505786455)
(HER2,2.8701690505786455)
(associated,2.8701690505786455)
(However,2.8701690505786455)
(imaging,2.505525936990736)
(rapidly,2.3513752571634776)
(fee-for-service,2.3513752571634776)
(presenting,2.3513752571634776)
(techniques,2.3513752571634776)
(1200,2.3513752571634776)
(formulation,2.3513752571634776)
(Observational,2.3513752571634776)
(body,2.3513752571634776)
(ondata,2.3513752571634776)
(conventional,2.3513752571634776)
(Selective,2.3513752571634776)
(special,2.3513752571634776)
(protected,2.3513752571634776)
(harmless,2.3513752571634776)
(general,2.3513752571634776)
(tend,2.3513752571634776)
(physical,2.3513752571634776)
(side,2.3513752571634776)
(53.7,2.3513752571634776)
(present,2.3513752571634776)
(35,2.3513752571634776)
(adjustment,2.3513752571634776)
(medicine,2.3513752571634776)
(0.50-0.99;,2.3513752571634776)
(assessment,2.3513752571634776)
(evidenced,2.3513752571634776)
(highest,2.3513752571634776)
(scrutiny,2.3513752571634776)
(PI3K/Akt/mTOR,2.3513752571634776)
(requiring,2.3513752571634776)
(Similar,2.3513752571634776)
(initial,2.3513752571634776)
(include,2.3513752571634776)
(flow,2.3513752571634776)
(.013,2.3513752571634776)
(2012,2.3513752571634776)
(palliative,2.3513752571634776)
(concept,2.3513752571634776)
(Extra-Terminal,2.3513752571634776)
(6.1%,2.3513752571634776)
(intervention,2.3513752571634776)
(CIs,2.3513752571634776)
(adoption,2.3513752571634776)
(44%,2.3513752571634776)
(MEK,2.3513752571634776)
(suggesting,2.3513752571634776)
(recovery,2.3513752571634776)
(counseling,2.3513752571634776)
(Group,2.3513752571634776)
(generated,2.3513752571634776)
(rising,2.3513752571634776)
(prescriptions,2.3513752571634776)
(Ulm,2.3513752571634776)
(immunohistochemistry,2.3513752571634776)
(<,2.3513752571634776)
(asymptomatic,2.3513752571634776)
(improve,2.3513752571634776)
(monitoring,2.3513752571634776)
(will,2.3513752571634776)
(carcinogenesis,2.3513752571634776)
(analyzing,2.3513752571634776)
(combination,2.3513752571634776)
(agreement,2.3513752571634776)
(3,2.3513752571634776)
(system-both,2.3513752571634776)
(hinder,2.3513752571634776)
(intrauterine,2.3513752571634776)
(test,2.3513752571634776)
(LEVEL,2.3513752571634776)
(paradigm,2.3513752571634776)
(molecule,2.3513752571634776)
(inhibitory,2.3513752571634776)
(high-dose,2.3513752571634776)
(Bromodomain,2.3513752571634776)
(Because,2.3513752571634776)
(resonance,2.3513752571634776)
(01.01.2010,2.3513752571634776)
(editing,2.3513752571634776)
(Tumour,2.3513752571634776)
(death,2.3513752571634776)
(acute,2.3513752571634776)
(investigations,2.3513752571634776)
(criteria,2.3513752571634776)
(barriers,2.3513752571634776)
(latest,2.3513752571634776)
(Notably,2.3513752571634776)
(date,2.3513752571634776)
(Aims,2.3513752571634776)
(p,2.3513752571634776)
(allowed,2.3513752571634776)
(mice,2.3513752571634776)
(IMAGING,2.3513752571634776)
(intravenous,2.3513752571634776)
(properly,2.3513752571634776)
(People,2.3513752571634776)
(drains,2.3513752571634776)
(increment,2.3513752571634776)
(monoclonal,2.3513752571634776)
(Colorectal,2.3513752571634776)
(pursue,2.3513752571634776)
(36,2.3513752571634776)
(recombination,2.3513752571634776)
(method,2.3513752571634776)
(confirmation,2.3513752571634776)
(required,2.3513752571634776)
(predictive,2.3513752571634776)
(Fatigue.In,2.3513752571634776)
(56%,2.3513752571634776)
(subcutaneous,2.3513752571634776)
(10.0%,2.3513752571634776)
(greater,2.3513752571634776)
(met,2.3513752571634776)
(Nine,2.3513752571634776)
(ER+,2.3513752571634776)
(remained,2.3513752571634776)
(imagesneed,2.3513752571634776)
(Both,2.3513752571634776)
(proportional,2.3513752571634776)
(Meta-regression,2.3513752571634776)
(moist,2.3513752571634776)
(Raf,2.3513752571634776)
(rapid,2.3513752571634776)
(46.0,2.3513752571634776)
(preclinical,2.3513752571634776)
(fluorescence,2.3513752571634776)
(MAGN,2.3513752571634776)
(protocol,2.3513752571634776)
(spite,2.3513752571634776)
(calculate,2.3513752571634776)
(ERK,2.3513752571634776)
(Unfortunately,2.3513752571634776)
(substantial,2.3513752571634776)
(tumour-related,2.3513752571634776)
(simplify,2.3513752571634776)
(Better,2.3513752571634776)
(continuing,2.3513752571634776)
(considering,2.3513752571634776)
(induction,2.3513752571634776)
(motivation,2.3513752571634776)
(relative,2.3513752571634776)
(preliminary,2.3513752571634776)
(symptom,2.3513752571634776)
(classify,2.3513752571634776)
(52,723,2.3513752571634776)
(14,2.3513752571634776)
(refractory,2.3513752571634776)
(stratified,2.3513752571634776)
(60%,2.3513752571634776)
(underwent,2.3513752571634776)
(evaluated,2.3513752571634776)
(Technical,2.3513752571634776)
(alternative,2.3513752571634776)
(routinely,2.3513752571634776)
(excision,2.3513752571634776)
(ion,2.3513752571634776)
(similar,2.3513752571634776)
(values,2.3513752571634776)
(AND,2.3513752571634776)
(15.3%,2.3513752571634776)
(8/18,2.3513752571634776)
(personalistic,2.3513752571634776)
(purposively,2.3513752571634776)
(States,2.3513752571634776)
(500,000,2.3513752571634776)
(checkpoint,2.3513752571634776)
(comprehensive,2.3513752571634776)
(system,number,2.3513752571634776)
(optoacoustic,2.3513752571634776)
(formation,2.3513752571634776)
(Information,2.3513752571634776)
(generally,2.3513752571634776)
(inquiry,2.3513752571634776)
(clustering,2.3513752571634776)
(variable,2.3513752571634776)
(intra-operative,2.3513752571634776)
(trastuzumab-induced,2.3513752571634776)
(0.70,2.3513752571634776)
(0.049,2.3513752571634776)
(12.4%,2.3513752571634776)
(regional,2.3513752571634776)
(frequently,2.3513752571634776)
(developments,2.3513752571634776)
(PR,2.3513752571634776)
(dynamic,2.3513752571634776)
(Negative,2.3513752571634776)
(choice,2.3513752571634776)
(avoid,2.3513752571634776)
(b-cryptoxanthin,2.3513752571634776)
(PubMed,2.3513752571634776)
(semi-quantitatively,2.3513752571634776)
(chromatin,2.3513752571634776)
(consultation,2.3513752571634776)
(DWI,2.3513752571634776)
(yielded,2.3513752571634776)
(utilized,2.3513752571634776)
(P,2.3513752571634776)
(apoptosis,2.3513752571634776)
(corresponding,2.3513752571634776)
(CDDP,2.3513752571634776)
(exploit,2.3513752571634776)
(prediagnosis,2.3513752571634776)
(microRNA,2.3513752571634776)
(experiment,2.3513752571634776)
(Result,2.3513752571634776)
(applications,2.3513752571634776)
(towavelet,2.3513752571634776)
(93.45%,2.3513752571634776)
(advance,2.3513752571634776)
(trial,2.3513752571634776)
(replaced,2.3513752571634776)
(January,2.3513752571634776)
(clearly,2.3513752571634776)
(28,2.3513752571634776)
(37.5%,2.3513752571634776)
(policy,2.3513752571634776)
(sampling,2.3513752571634776)
(inhibitor-,2.3513752571634776)
(collected,2.3513752571634776)
(BMI,2.3513752571634776)
(DiR,2.3513752571634776)
(Forty-two,2.3513752571634776)
(directly,2.3513752571634776)
(0.015,2.3513752571634776)
(ILC,2.3513752571634776)
(length,2.3513752571634776)
(Guided,2.3513752571634776)
(focusing,2.3513752571634776)
(Transcripts,2.3513752571634776)
(retinol,2.3513752571634776)
(causation,2.3513752571634776)
(search,2.3513752571634776)
(P=0.2,2.3513752571634776)
(shared,2.3513752571634776)
(multiresolution,2.3513752571634776)
(spectrometry,2.3513752571634776)
(23,2.3513752571634776)
(bed,2.3513752571634776)
(compare,2.3513752571634776)
(discomfort,2.3513752571634776)
(addition,2.3513752571634776)
(Finally,2.3513752571634776)
(face-to-face,2.3513752571634776)
(summarize,2.3513752571634776)
(potent,2.3513752571634776)
(compounds,2.3513752571634776)
(3.5,2.3513752571634776)
(misdiagnosis,2.3513752571634776)
(definitive,2.3513752571634776)
(OF,2.3513752571634776)
(validated,2.3513752571634776)
(50,2.3513752571634776)
(proportion,2.3513752571634776)
(adjuvant,2.3513752571634776)
(Osteopontin-750,2.3513752571634776)
(unenhanced,2.3513752571634776)
(Objective,2.3513752571634776)
(ratio,2.3513752571634776)
(atechnique,2.3513752571634776)
(shift,2.3513752571634776)
(assessed,2.3513752571634776)
(intensity,2.3513752571634776)
(1062,2.3513752571634776)
(behaviors,2.3513752571634776)
(Methods,2.3513752571634776)
(negligible,2.3513752571634776)
(diagnoses,2.3513752571634776)
(study;,2.3513752571634776)
(Six,2.3513752571634776)
(overview,2.3513752571634776)
(larger,2.3513752571634776)
(theory,2.3513752571634776)
(numbers,2.3513752571634776)
(explained,2.3513752571634776)
(Diagnostic,2.3513752571634776)
(An,2.3513752571634776)
(examinations,2.3513752571634776)
(update,2.3513752571634776)
(lower,2.3513752571634776)
(investigate,2.3513752571634776)
(broader,2.3513752571634776)
(Interestingly,2.3513752571634776)
(At,2.3513752571634776)
(MCL-1,2.3513752571634776)
(lutein,2.3513752571634776)
(filters,2.3513752571634776)
(offer,2.3513752571634776)
(biocompatibility,2.3513752571634776)
(RESON,2.3513752571634776)
(ER,2.3513752571634776)
(estradiol,2.3513752571634776)
(Multivariate,2.3513752571634776)
(interview,2.3513752571634776)
(signaling,2.3513752571634776)
(6.8%,2.3513752571634776)
(Ten,2.3513752571634776)
(Noteworthy,2.3513752571634776)
(p53,2.3513752571634776)
(breast-conserving,2.3513752571634776)
(cost,2.3513752571634776)
(precision,2.3513752571634776)
(Given,2.3513752571634776)
(radiologists,2.3513752571634776)
(prior,2.3513752571634776)
(detectionof,2.3513752571634776)
(investigation,2.3513752571634776)
(reproducibility,2.3513752571634776)
(phantom,2.3513752571634776)
(helps,2.3513752571634776)
(self-examination,2.3513752571634776)
(summarized,2.3513752571634776)
(paper,2.3513752571634776)
(All,2.3513752571634776)
(BAK,2.3513752571634776)
(hormone,2.3513752571634776)
(38.7%,2.3513752571634776)
(shaped,2.3513752571634776)
(1,444,2.3513752571634776)
(segmentation,2.3513752571634776)
(estimated,2.3513752571634776)
(oxide,2.3513752571634776)
(IO-NP,2.3513752571634776)
(versus,2.3513752571634776)
(trastuzumab,2.3513752571634776)
(Comparison,2.3513752571634776)
(0.75-1.09,2.3513752571634776)
(HER4,2.3513752571634776)
(crucial,2.3513752571634776)
(difficult,2.3513752571634776)
(17,2.3513752571634776)
(lethality,2.3513752571634776)
(breasts,2.3513752571634776)
(cancercells,2.3513752571634776)
(onset,2.3513752571634776)
(subtype,2.3513752571634776)
(acquisition,2.3513752571634776)
(finances,2.3513752571634776)
(ml,2.3513752571634776)
(network,2.3513752571634776)
(capecitabine,2.3513752571634776)
(multispectral,2.3513752571634776)
(HER3,2.3513752571634776)
(vs,2.3513752571634776)
(leading,2.3513752571634776)
(Efficacy,2.3513752571634776)
(pattern,2.3513752571634776)
(54%,2.3513752571634776)
(modified,2.3513752571634776)
(pathological,2.3513752571634776)
(applicable,2.3513752571634776)
(5,2.3513752571634776)
(1996,2.3513752571634776)
(31.12.2014,2.3513752571634776)
(Centre,2.3513752571634776)
(aggressive,2.3513752571634776)
(So,2.3513752571634776)
(inception,2.3513752571634776)
(Cardiac,2.3513752571634776)
(noncoding,2.3513752571634776)
(computed,2.3513752571634776)
(43.6,2.3513752571634776)
(coronary,2.3513752571634776)
(mortality,2.3513752571634776)
(Anthracyclines,2.3513752571634776)
(Ulceration,2.3513752571634776)
(BAX,2.3513752571634776)
(inclusion,2.3513752571634776)
(pill,2.3513752571634776)
(wider,2.3513752571634776)
(administration,2.3513752571634776)
(treatment;,2.3513752571634776)
(Among,2.3513752571634776)
(normal,2.3513752571634776)
(T/B,2.3513752571634776)
(adjusted,2.3513752571634776)
(scan,2.3513752571634776)
(typical,2.3513752571634776)
(Ag2S-NP,2.3513752571634776)
(cardiotoxicities,2.3513752571634776)
(VEGFB,2.3513752571634776)
(recently,2.3513752571634776)
(occurred,2.3513752571634776)
(copyright,2.3513752571634776)
(2.5 h,2.3513752571634776)
(Ras,2.3513752571634776)
(AZD2281,2.3513752571634776)
(peptide,2.3513752571634776)
(distinguish,2.3513752571634776)
(interpretation,2.3513752571634776)
(well,2.3513752571634776)
(discovered,2.3513752571634776)
(lag,2.3513752571634776)
(defined,2.3513752571634776)
(Anti-HER2,2.3513752571634776)
(occurrence,2.3513752571634776)
